 Thanks to its leading positions in various therapeutic areas, Mercks revenue was 14,959 million in Q3 2022, an increase of 13.7 compared to the previous year. In September 2022, Japan MHLW approved the expansion of the use of Keytruda for the treatment of various types of cancer. 